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Transcription factors Tp73, Cebpd, Pax6, and
Spi1 rather than DNA methylation regulate
chronic transcriptomics changes after
experimental traumatic brain injury
Anssi Lipponen1, Assam El-Osta2,3, Antony Kaspi2, Mark Ziemann2, Ishant Khurana2, Harikrishnan KN2,
Vicente Navarro-Ferrandis1, Noora Puhakka1, Jussi Paananen4,5 and Asla Pitkänen1*
Abstract
Traumatic brain injury (TBI) induces a wide variety of cellular and molecular changes that can continue for days to
weeks to months, leading to functional impairments. Currently, there are no pharmacotherapies in clinical use that
favorably modify the post-TBI outcome, due in part to limited understanding of the mechanisms of TBI-induced
pathologies. Our system biology analysis tested the hypothesis that chronic transcriptomics changes induced by TBI
are controlled by altered DNA-methylation in gene promoter areas or by transcription factors. We performed
genome-wide methyl binding domain (MBD)-sequencing (seq) and RNA-seq in perilesional, thalamic, and
hippocampal tissue sampled at 3 months after TBI induced by lateral fluid percussion in adult male Sprague-Dawley
rats. We investigated the regulated molecular networks and mechanisms underlying the chronic regulation,
particularly DNA methylation and transcription factors. Finally, we identified compounds that modulate the
transcriptomics changes and could be repurposed to improve recovery. Unexpectedly, DNA methylation was not a
major regulator of chronic post-TBI transcriptomics changes. On the other hand, the transcription factors Cebpd,
Pax6, Spi1, and Tp73 were upregulated at 3 months after TBI (False discovery rate < 0.05), which was validated
using digital droplet polymerase chain reaction. Transcription regulatory network analysis revealed that these
transcription factors regulate apoptosis, inflammation, and microglia, which are well-known contributors to
secondary damage after TBI. Library of Integrated Network-based Cellular Signatures (LINCS) analysis identified 118
pharmacotherapies that regulate the expression of Cebpd, Pax6, Spi1, and Tp73. Of these, the antidepressant and/or
antipsychotic compounds trimipramine, rolipramine, fluspirilene, and chlorpromazine, as well as the anti-cancer
therapies pimasertib, tamoxifen, and vorinostat were strong regulators of the identified transcription factors,
suggesting their potential to modulate the regulated transcriptomics networks to improve post-TBI recovery.
Keywords: DNA methylation, LINCS analysis, MBD-seq, Recovery, RNA-seq, Treatment
Introduction
Every year, 2.5 million people in Europe and the USA sus-
tain traumatic brain injury (TBI) [15, 28, 74]. TBI is a
major cause of disability and death in patients younger
than 45 years of age [65]. Despite a large number of pre-
clinical and clinical studies, an effective pharmacotherapy
to improve post-TBI outcome is still lacking [22, 25, 76].
This is due in part to the complexity of the secondary
pathologies induced by TBI, including neurodegeneration,
inflammation, oxidative stress, axonal and myelin injury,
and vascular changes [64, 79, 80]. These pathologies pro-
gress in parallel and serial time windows over weeks to
months in experimental models [7, 46, 91, 112] and
humans [36, 49, 98]. As these observations suggest com-
plex and long-lasting transcriptomics regulation, we
propose that a network therapy rather than a
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monotherapy approach will be more effective for repair of
the ongoing damage.
To date, a number of studies have investigated tran-
scriptomics changes at a genome-wide scale at 24-48 h
after TBI [14, 17, 38, 42, 47, 48, 59, 63, 78, 85, 97, 99, 104,
122, 123, 125, 128–130, 136]. Of these 19 genome-wide
gene expression studies, 11 report dysregulation of tran-
scription factors in the acute post-TBI phase [17, 48, 59,
78, 85, 97, 104, 123, 128–130]. Four hypothesis-driven
analyses focusing on individual transcription factors report
the dysregulation of Jun [133], Cebpd [105], Runx1 [70],
and Olig2 [9] in the acute post-TBI phase. Most of the
studies, however, analyzed only acute post-TBI time-
points and a single brain area, typically the hippocampus
or cortex. Further, very few studies have explored the
mechanisms that regulate post-TBI gene expression, such
as genome-wide DNA methylation [20, 39, 83].
We hypothesized that TBI results in chronic tran-
scriptomics changes that are controlled by DNA-
methylation changes in the gene promoter areas or by
transcription factors. To test this, we induced TBI in rats
by lateral fluid-percussion, and subjected the perilesional
cortex, ipsilateral thalamus, and ipsilateral hippocampus
to MBD-seq and RNA-seq. As bioinformatics analysis
and laboratory validation indicated that transcription
factors rather than DNA methylation regulate chronic
transcriptomics changes, we further conducted LINCS
analysis to identify compounds that regulate gene ex-
pression of these transcription factors and could there-
fore be repurposed to improve post-TBI outcome via
transcription factor-mediated mechanisms.
Materials and methods
Animals
TBI was induced by lateral fluid-percussion injury (FPI)
with an impact pressure of 3.30 ± 0.01 atm in 14 adult
male Sprague-Dawley rats (330–370 g at the time of TBI
or sham operation; Harlan, The Netherlands) as previ-
ously described [54, 81]. Eleven sham-operated animals
served as experimental controls. At 3 months after TBI,
the perilesional cortex, thalamus, and hippocampus were
collected as described in Lipponen et al. [69]. Briefly, the
rats were anesthetized with 5% isoflurane and decapi-
tated. The brain was removed from the skull, flushed
with 0.9% cold (4 °C) sodium chloride, and placed onto
a slicing matrix on ice (#15007, Rodent Brain Matrix,
Ted Pella, Inc., Redding, CA, USA). Two 2-mm-thick
coronal slices were cut (between − 2.2 and − 6.2 from
the bregma), from which the perilesional cortex, ipsilat-
eral thalamus, and ipsilateral hippocampus (including
dentate gyrus) were dissected on top of the light table
under the magnifying glass. Brain tissue samples were
snap-frozen in liquid nitrogen, and stored at -70 °C until
RNA and DNA extraction.
All animal operations were approved by The Animal
Ethics Committee of the Provincial Government of
Southern Finland and carried out according to the
guidelines of the European Community Council Direc-
tives 2010/63/EU.
Preparation of MBD- and RNA-seq libraries and
sequencing
DNA and RNA extraction
Brain tissue from five TBI and five sham-operated rats
was used for methyl-binding domain sequencing (MBD-
seq) and RNA-sequencing (RNA-seq). DNA and RNA
were co-purified from the perilesional cortex, ipsilateral
hippocampus, or ipsilateral thalamus using a DNeasy
Blood&Tissue kit (#69504, Qiagen, Hilden, Germany).
Quality control of the total RNA was performed using a
MultiNA electrophoresis device (Shimazu, Kyoto, Japan).
RNA-seq library and sequencing
The mRNA library preparation and RNA-sequencing
were performed as described in Lipponen et al. [69].
Briefly, mRNA was enriched using Dynabeads Oligo
(dT)25 beads (#61002, Invitrogen, Carlsbad, CA, USA),
and the sequencing libraries were compiled with the
NEBNext mRNA Library Prep Reagent Set (#E6100S,
New England Biolabs, Ipswich, MA, USA). Quality con-
trol of the sequencing libraries was performed with a
MultiNA electrophoresis device (Shimazu, Kyoto, Japan).
Sequencing of the mRNA libraries for the perilesional
cortex and hippocampus was carried out with an Illu-
mina Genome Analyzer IIx (San Diego, CA, USA), and
for the thalamus using an Illumina HiSeq 2000 (San
Diego, CA, USA). The Illumina Off-Line Basecaller v1.8
was used for base-calling. RNA-seq raw data can be
downloaded from the NCBI Gene Expression Omnibus
(GEO; series accession number GSE80174).
MBD-seq library and sequencing
For MBD-seq, 2 μg of DNA was fragmented by sonic-
ation, and the quality was controlled with a MultiNA
electrophoresis device (Shimazu, Kyoto, Japan). Methyl-
ated DNA was enriched with a 2-M sodium chloride
elution using MethylMiner™kit (Thermo Fischer Scien-
tific, Waltham, MA, USA), and quantified using a Qubit
fluorometer (Thermo FisherScientific, Waltham, MA,
USA). The sequencing library was prepared from 5 ng of
enriched methylated DNA using an NEB Next DNA li-
brary kit (#E6040S, New England Biolabs, Ipswich, MA,
USA). Then, MBD-sequencing and base-calling for the
perilesional cortex, hippocampus, and thalamus were
carried out as described above. Raw MBD-seq data was
saved to the NCBI Gene Expression Omnibus (GEO;
series accession number GSE107837).
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Mapping of sequencing data, and identification of
differentially methylated regions and differentially
expressing genes
Methylation
Quality control of the MBD-sequencing raw reads was
performed using FastQC [3]. Sequencing raw reads were
mapped to the Ensemble RN5 genome with Spliced
Transcripts Alignment to a Reference (STAR) software
(version 2.3.0e_r291) [24] with parameter alignIntron-
Max 1 to prohibit splicing and allow genomic mapping.
The mapping percentages were 71.2 ± 4.0% for the peri-
lesional cortex, 63.3 ± 3.2% for the ipsilateral hippocam-
pus, and 71.3 ± 2.7% for the ipsilateral thalamus.
Differentially-methylated gene promoters (5000 bp up-
stream and 200 bp downstream from the transcription
start site), exons, and gene body area were identified
with blocksStats function in the Repitools 1.21.1 R pack-
age [115] with R version 3.1.0. The adjusted p-value was
calculated with a Benjamini–Hochberg false discovery
rate (FDR). DNA methylation was considered signifi-
cantly changed if the FDR was < 0.05.
Gene expression
RNA-seq quality control, mapping, and identification of
differentially expressed genes were previously described
in detail (Lipponen et al. 2016) [69]. Shortly, quality con-
trol of the RNA-seq reads was performed using FastQC
[3] and reads were aligned to the Ensemble RN5 genome
with STAR software (version 2.3.0e_r291) [24]. Differen-
tially expressed genes were identified with DEseq2 [72]
R package (R version 3.1.0) and the Benjamini–Hoch-
berg false discovery rate (FDR) was used to calculate the
adjusted p-value. Gene expression was considered to be
significantly differentially expressed when FDR < 0.05.
Effect of DNA methylation in the promoter, exon, or gene
body region on gene expression
Gene set enrichment analysis
To analyze the effect of DNA methylation located in the
gene promoter, exon, or gene body areas on gene ex-
pression, we performed Gene Set Enrichment Analysis
(GSEA) [116]. First, we prepared ranked lists from the
gene expression data in the perilesional cortex, hippo-
campus, and thalamus by ranking the genes in order ac-
cording to the p-value of mRNA differential expression.
Upregulated genes were assigned with a positive rank
number and downregulated genes with a negative rank
number. Then, we generated three gene sets (genes with
differentially methylated promoters, exons, or gene body
areas) from each of the three brain areas (perilesional
cortex, hippocampus, thalamus). Enrichment of these
sets within the ranked lists was studied using GSEA, and
enrichment was considered significant when the FDR q-
value was < 0.05.
Linear regression analysis
To confirm the GSEA results, we analyzed the associ-
ation of DNA methylation in the gene promoter, exon,
and gene body areas on gene expression using two dif-
ferent linear regression models: (a) association of DNA
methylation on gene expression, (b) association of TBI
on gene expression via DNA methylation. Regression
analysis was carried out with lm-function in R v3.1.0.
Genes with average mRNA read number < 50 were fil-
tered out from the analysis. Regression was considered
significant when FDR < 0.05.
Validation of gene promoter methylation and gene
expression
Digital droplet polymerase chain reaction (ddPCR) and
pyrosequencing were used to confirm the gene expres-
sion changes in the RNA-seq and the methylation
changes in the MBD-seq, respectively, of the four top
hits. Of the four top hits, Gpr12 and Lrp1b were down-
regulated in the mRNA-seq and showed increased pro-
moter methylation in the MBD-seq in the perilesional
cortex, Ppid showed increased promoter methylation in
the thalamus, and Wdr26 showed increased promoter
methylation in the hippocampus (Table 1).
Table 1 Gene promoter methylation and gene expression of
Wdr26, Lrp1b, Ppid and Gpr12 in perilesional cortex, hippocampus
and ipsilateral thalamus according MBD and RNA-seq
Wdr26 Lrp1b Ppid Gpr12
Perilesional Cx Gene expression
log2FC − 0.161 − 0.441 − 0.222 − 0.531
FDR 0.300607 0.022273 0.242403 0.000197
Methylation
log2FC 0.313 1.402 0.038 1.407
FDR 1 0.01901 1 0.014662
Hippocampus Gene expression
log2FC −0.129 −0.166 −0.036 0.224
FDR 0.999825 0.999825 0.999825 0.999825
Methylation
log2FC 2.660 −0.602 1.930 0.179
FDR 1.87E-14 1 1.4E-07 1
Thalamus Gene expression
log2FC 0.140 −0.097 −0.074 − 0.687
FDR 0.721246 0.795279 0.873954 0.000388
Methylation
log2FC 0.241 0.159 0.059 −0.014
FDR 1 1 1 1
Abbreviations: Cx perilesional cortex, FC fold-change. Statistical significances:
log2FC change and corresponding FDR (< 0.05) are shown in bolded font
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Extraction of RNA for ddPCR and DNA for pyrosequencing
Brain tissue from nine TBI and six sham-operated ani-
mals was collected as described above. The animals
belonged to the same cohort of injured rats used for the
RNA-seq and MBD-seq analyses.
RNA and DNA were extracted simultaneously from
the perilesional cortex, thalamus, or hippocampus using
a mirVana miRNA isolation kit (#AM1560, Life Tech-
nologies (Ambion) Carlsbad, CA, USA), QIAshredder
(#79654, Qiagen), and AllPrep DNA/RNA Mini Kit
(#80204, Qiagen) as previously described [90]. Briefly, to
avoid clogging the spin columns, brain tissue was di-
vided into 2–5 pieces (each ~ 10 mg) on dry ice. Each
tissue piece was then placed into a 2-ml microcentrifuge
tube together with one metal ball and 800 μl of Ambion
Lysis/binding buffer, and homogenized with a TissueLy-
ser (Qiagen) for 3 min (30 Hz). For further
homogenization, the lysate was transferred to a QIA-
shedder spin column and centrifuged (16,000 g) for
2 min at 4 °C. Flow-through lysate was transferred back
to the QIAshedder spin column and centrifuged again.
For DNA extraction, lysate was transferred to a Qiagen
All Prep DNA spin column and centrifuged (10,000 g)
for 1 min at room temperature. The spin-column was
washed and eluted according to the instructions pro-
vided in the AllPrep DNA/RNA Mini Kit for DNA
extraction.
Flow-through from the All Prep DNA spin column
was used for RNA extraction using a mirVana miRNA
isolation kit. Briefly, miRNA homogenate additive
(70 μl) was added to the flow-through. The mixture was
vigorously vortexed for 30 s and then incubated on ice
for 10 min. Acid-phenol:chloroform (700 μl) was then
added, mixed, and centrifuged (16,000 g) for 30 s. The
aqueous upper phase was transferred to a new micro-
centrifuge tube. Five hundred microliters of water was
added to the lower phase, mixed, and centrifuged
(16,000 g) for 30 s. The upper aqueous phase was col-
lected into the same tube as the aqueous phase from the
previous extraction cycle. Then, 100% ethanol (625 μl)
was added to the tube, mixed, and transferred to the
mirVana miRNA isolation spin column. Finally, RNA
was washed and eluted from the spin column according
to instructions provided with the mirVana miRNA isola-
tion kit. Finally, RNA extracted from each brain region
was pooled.
Pyrosequencing
Percentage (ratio of methylated/nonmethylated DNA *
100) of DNA methylated cytosines at a given CpG site in
the Ppid, Lrp1b, or Wrd26 gene promoters, or at two
CpG sites in the Gpr12 promoter was measured with
pyrosequencing using the PSQ 96MA 2.1 platform (Bio-
tage AB, Uppsala, Sweden) in the Genome Center of the
University of London (Additional file 1). The Mann-
Whitney U test was used to assess the significance of the
difference in the percentage of methylation between the
TBI and sham-operated animals (p < 0.05 was considered
statistically significant) (Table 2).
ddPCR
RNA quality was checked with a 2100 Bioanalyzer (Agi-
lent, Santa Clara, CA, USA) and RNA 6000 Nano Kit
(#5067–1511, Agilent). The RNA integrity number
(RIN) was > 8.0 in all but one sample (RIN 7.8). There-
fore, 50 ng of RNA from all 15 samples was translated
to cDNA using an iScript Advanced cDNA synthesis kit
(#172–5038, BioRad, Hercules, CA, USA). Gene expres-
sion of Ppid, Gpr12, Lrp1b, and Wrd26 was validated
by ddPCR using Actb as a reference gene. ddPCR was
conducted using QX200 ddPCR EvaGreen Supermix so-
lution (#186–4033, BioRad) and a PrimerPCR gene ex-
pression assay (Actb; #dRnoEG5146006, Gpr12;
#dRnoEG5125945, Lrp1b; #dRnoEG5140109, Ppid;
#dRnoEG5125166, Wdr26; #dRnoEG5145659, BioRad)
according to the manufacturer’s instructions. Droplets
were generated and their fluorescence measured with a
QX200 Droplet Digital PCR System (BioRad). Fluores-
cent droplets were classified as “positive” and “negative”,
and then the concentration of each gene (copy/μl) was
calculated using QuantaSoft 1.7.4 (BioRad). Target gene
concentrations were normalized according to the Actb
reference gene, log2 fold-changes were calculated, and
the significance in the difference in droplet counts be-
tween the TBI and sham-operated rats was assessed
using the Mann-Whitney U test (Table 2).
Identification of transcription factors that chronically
regulate post-TBI transcriptomics
Transcription regulatory network of the perilesional cortex
and ipsilateral thalamus
To analyze the regulation of post-TBI transcriptomics by
transcription factors in the perilesional cortex and ipsi-
lateral thalamus, and to further visualize their target
genes, we downloaded the transcription regulatory net-
work (TRN) from the SignaLink 2.0 database [31, 60].
Then, RNA-seq data from both brain areas (fold-change
and FDR between sham-operated experimental controls
and TBI animals) was integrated with the SignaLink 2.0
TRN in Cytoscape 3.4 [108]. To visualize the regulated
targets of each selected transcription factor, differentially
expressed transcription factors in mRNA-seq (FDR <
0.05 and log2FC < − 1 or > 1) and their nearest down-
stream neighbors in the TRN were detached from the
SignaLink 2.0 network. Further analysis focused on the
four transcription factors that had the highest number of
regulated target genes in TRN.
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Validation of gene expression of the top four
transcription factors
ddPCR
Digital droplet PCR of the four top transcription factors
(Cebpd, Pax6, Spi1, and Tp73) using Actb as a refer-
ence gene was performed to confirm the change in the
expression of transcription factors coding genes. Ana-
lysis was performed using the same RNA samples,
cDNA synthesis method, and ddPCR EvaGreen Super-
mix solution as for the validation of MBD-seq data (see
above). A PrimerPCR gene expression assay (Actb;
#dRnoEG5146006, Cebpd; #dRnoEG5126239, Pax6;
#dRnoEG5125771, Spi1; #dRnoEG5139059, Tp73;
#dRnoEG5139860, BioRad) was performed according to
the manufacturer’s instructions. Droplets were generated
and their fluorescence measured with the QX200 Drop-
let Digital PCR System. QuantaSoft 1.7.4 was used to
classify droplets as “positive” and “negative”, and to cal-
culate the concentration of gene copies/μl as described
earlier. Finally, the target gene concentration was nor-
malized with the reference gene concentration, the log2
fold-change of the concentration was calculated, and the
significance in the difference in concentrations between
the TBI and sham-operated rats was assessed using the
Mann-Whitney U test.
Identification of compounds modifying the transcription
factor gene expression with the LINCS database
Compounds modifying transcription factors gene expression
Next, we searched the LINCS database (http://data.lincsclou-
d.org.s3.amazonaws.com/index.html) to identify compounds
that modify the expression of the four top transcription factors
revealed by the SignaLink 2.0 database analysis. An in-house–
created R script was used to run LINCS through an applica-
tion programming interface. Reproducible compound-induced
transcriptomics changes in terminally differentiated neurons
(NEU), terminally differentiated neurons treated with KCl
(NEU.KCL), and induced pluripotent stem cells-derived neural
progenitor cells (NPC) were included in the analysis. As a re-
sult, we obtained a list of compounds that modulated the ex-
pression of transcription factors in one to three cell lines (i.e.,
transcription factors were within the 100 most upregulated or
100 most downregulated genes by a given compound).
Results
TBI-induced gene expression changes after TBI were most
prominent in the perilesional cortex and were associated
with DNA methylation at the gene promoter region
GSEA analysis of MBD-seq data
GSEA analysis of the perilesional cortex MBD-seq data
suggested that altered DNA methylation in the gene
Table 2 Validation of gene promoter methylation by pyrosequencing and gene expression by ddPCR in the perilesional cortex,
thalamus and hippocampus. As negative controls, we also assessed the methylation and gene expression in the ipsilateral
hippocampus and thalamus. Wdr26, Lrp1b, and Ppid genes had only one CpG site whereas Gpr12 gene had two CpG sites
Wdr26 Lrp1b Ppid Gpr12
Perilesional Cx Gene expression
Log2FC −0.94944 − 0.17498 − 0.60015 −0.37159
p-value 0.007592 0.7756 0.03596 0.3277
Methylation
Average methylation (%) 85.31 67.28 59.52 CpG site1: 73.43 CpG site2: 76.57
Difference TBI - sham (%) 1.07 −0.17 2.39 CpG site1:0.43 CpG site2:0.35
p-value 0.1135 0.9546 0.3636 CpG site1: 0.8639 CpG site2: 1
Hippocampus Gene expression
Log2FC −0.6746 −0.6457 −1.3397 −0.3415
p-value 0.366 0.1375 0.366 0.366
Methylation
Average methylation (%) 87.22 59.92 57.25 CpG site1: 69.06 CpG site2: 73.48
Difference TBI - sham (%) 1.10 −2.73 2.65 CpG site1: 1.70 CpG site2: −0.59
p-value 0.366 0.2343 0.366 CpG site1: 0.5338 CpG site2: 1
Thalamus Gene expression
Log2FC −0.8936 −0.4964 −0.9309 −1.3735
p-value 0.181 0.3277 0.06633 0.001598
Methylation
Average methylation (%) 85.11 65.82 49.95 CpG site1: 74.23 CpG site2: 77.40
Difference TBI - sham (%) 1.07 −2.33 7.69 CpG site1: −0.95 CpG site2: −0.93
p-value 0.1469 0.5287 0.3884 CpG site1: 0.7756 CpG site2: 0.1135
Abbreviations: Cx cortex, FC fold-change. Statistical significances: log2FC change and corresponding p-value (< 0.05) are shown in bolded font
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promoter area was inversely associated with the global
gene expression profile (FDR q-val. 0.046) (Fig. 1). Al-
tered DNA methylation in the gene promoter area in the
hippocampal (FDR q-val. 0.079) or thalamic samples
(FDR q-val. 0.828), however, was not associated with
regulated gene expression. Interestingly, changes in
DNA methylation in exons were not associated with
gene expression in the perilesional cortex (FDR q-val.
0.243), hippocampus (FDR q-val. 0.464), or thalamus
(FDR q-val. 0.372). DNA methylation in the gene body
area also was not associated with transcriptomics
changes in the perilesional cortex (FDR q-val. 0.083),
thalamus (FDR q-val. 0.256), or hippocampus (FDR q-
val. 0.631).
Linear regression analysis of the MBD-seq data
To find individual genes affected by DNA methylation
and TBI from the global DNA methylation profile, we
performed a regression analysis to separately assess the
TBI effect and methylation effect on gene expression. In
the perilesional cortex and ipsilateral thalamus, however,
we observed no TBI-induced effect on DNA methylation
of individual genes when the gene promoter, exon, or
gene body areas were analyzed separately. In contrast, in
the hippocampus, TBI affected the DNA methylation of
Crybg3 (FDR = 0.0347, estimate = − 1.105 (95% confi-
dence interval [CI]: − 1.2517 to − 0.9598) and Mak16
(FDR = 0.0356, estimate = 4.596, 95% CI: 3.9705 to
5.2219) promoters, which affected their target gene ex-
pression. in the hippocampus, no TBI effect on methyla-
tion was detected in the exon and gene body regions.
We also used regression analysis to investigate the
DNA methylation effect on gene expression. DNA
methylation in any of the genomic areas did not appear
to affect gene expression in any of the studied brain
regions.
Methylation of the promoter area
Analysis of MBD-seq data revealed significantly regu-
lated DNA methylation in the promoter regions of 29
genes (all with increased methylation) in the perilesional
cortex (FDR < 0.05). In four of 29 genes (RGD1566265,
Nap1l2, Lrp1b, and Gpr12), an increase in promoter
methylation was associated with reduced gene expression
in the corresponding perilesional cortex (FDR < 0.05). In
the hippocampus, none of the 166 methylation changes
(97 increased and 69 decreased) in the promoter area were
Fig. 1 Enrichment scores of Gene Set Enrichment Analysis (GSEA) of
DNA methylation in gene promoters in the (a) perilesional cortex (b)
ipsilateral hippocampus, and (c) ipsilateral thalamus at 3 months after
TBI. GSEA indicated significant negative enrichment in the perilesional
cortex (FDR q-val. 0.046), but not in the ipsilateral hippocampus (FDR
q-val. 0.079) or ipsilateral thalamus (FDR q-val. 0.828)
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associated with changes in gene expression. In the thal-
amus, no alterations in promoter methylation were found
(FDR < 0.05).
Methylation of exons
Methylation in exons of 20 genes (15 increased and 5
decreased) was regulated in the hippocampus, but none
of the methylation changes were associated with altered
expression of the corresponding gene in the RNA-seq
data (FDR < 0.05). In the perilesional cortex and thal-
amus, we observed no changes in exon methylation
(FDR < 0.05).
Methylation of gene body areas
Methylation of the gene body area was not changed in
any of the brain areas studied (FDR < 0.05).
Validation of MBD-seq using pyrosequencing and RNA-
seq data using ddPCR failed to confirm a link between
promoter methylation and changed gene expression in
the perilesional cortex at 3 months after TBI
Validation of gene promoter area methylation and gene
expression
Promoter methylation and expression of Lrp1b, Gpr12,
Wrd26, and Ppid genes in the perilesional cortex were
validated with pyrosequencing and ddPCR, respectively,
in animals from the same cohort used for the RNA-seq
and MBD-seq studies (Table 2). The percentage of
methylation per CpG site in the promoter region varied
from 49.95 to 87.22%, depending on the gene or the
methylation site in each gene (Table 2). Unexpectedly,
pyrosequencing indicated that none of the four tested
genes in the perilesional cortex had altered methylation
in the gene promoter area (Table 2). ddPCR, however,
confirmed reduced expression of Wrd26 and Ppid in
the perilesional cortex (Table 2).
Post-TBI perilesional cortex showed a substantial increase
in the expression of four transcription factors
Transcription factors regulating post-TBI gene expression
As we observed few methylation changes in relation to
the large number of transcriptomic changes in the peri-
lesional cortex and ipsilateral thalamus, we next assessed
whether chronic post-TBI regulation of gene expression
in these brain areas was controlled by transcription fac-
tors. To assess whether the transcriptomic changes ob-
served in RNA-seq correspond to alterations in local cell
populations we correlated the read counts of transcrip-
tion factors with the read counts of neuronal, microglial
and astroglial markers (Additional files 2 and 3).
Transcription regulatory network of the perilesional cortex
In the perilesional cortex, integration of SignaLink 2.0
TRN and RNA-seq revealed increased expression in five
transcription factors, Pax6 (Fig. 2), Tp73 (Fig. 3),
Cebpd, Spi1, and Myb, and decreased expression in
Etv4 at 3 months post-TBI (Table 3). Pax6 had 300 tar-
gets in the TRN analysis, of which 32 were upregulated
and 59 downregulated. Tp73 had 54 targets in the TRN
analysis, of which five were upregulated and 11 down-
regulated. Igf1, the only target of Cebpd, was upregu-
lated in the TRN analysis. Spi1 had three targets in the
TRN analysis, of which only Lsp1 was upregulated. Ac-
cording to the TRN analysis, Etv4 had one target, which
did not show altered gene expression. In the TRN ana-
lysis, Myb had three targets, none of which showed al-
tered expression in the perilesional cortex.
Validation of transcription factor expression in the
perilesional cortex after TBI
In the perilesional cortex, validation confirmed a signifi-
cant increase in gene expression of Cebpd (p =
0.0003996), Pax6 (p = 0.004795), Spi1 (p = 0.007592),
and Tp73 (p = 0.0007992) (Table 4) at 3 months after
TBI.
Transcription regulatory network of the ipsilateral thalamus
TRN analysis of the ipsilateral thalamus revealed upregu-
lation of Pax6, Cebpd, and Spi1, and downregulation of
the Etv4 transcription factor at 3 months post-TBI (Table
3). Pax6 had 19 targets that were upregulated and 14 tar-
gets that were downregulated. Igf1, the only target of
Cebpd, was upregulated. Spi1 had one upregulated target,
Lsp1. Etv4 showed no alteration in gene expression.
Validation of transcription factor expression in the
ipsilateral thalamus and hippocampus after TBI
In the ipsilateral thalamus, validation of gene expression in-
dicated a trend toward increased expression of Spi1 (p =
0.06633), but not Cebpd (p = 0.2721), Pax6 (P = 0.4559), or
Tp73 (p = 0.3884) (Table 4) at 3 months after TBI. In the
ipsilateral hippocampus, gene expression was unchanged.
LINCS analysis revealed 118 candidate pharmacotherapies
that can regulate transcription factors
Pharmacotherapies regulating transcription factor gene
expression
The LINCS database analysis revealed 118 pharmaco-
therapies that can modify the gene expression of the top
four transcription factors (Pax6, Tp73, Cebpd, and
Spi1) (Table 5). Expression of Cebpd was upregulated
by 92 compounds and downregulated by two com-
pounds. Pax6 was upregulated by eight compounds and
downregulated by six compounds. Spi1 was upregulated
by two compounds and downregulated by three com-
pounds. Tp73 was upregulated by five compounds.
Interestingly, none of the compounds regulated more
than one transcription factor.
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Discussion
In the present study, we evaluated whether TBI induces
long-lasting transcriptomics regulation that is under the
control of DNA-methylation. Bioinformatics analysis indi-
cated that transcription factors rather than DNA methyla-
tion regulate gene expression at 3 months after TBI.
Further, LINCS analysis revealed that several drugs already
in clinical use modulate the expression of the identified key
regulatory transcription factors Cebpd, Pax6, Spi1, and
Tp73.
DNA methylation is not a major regulator of chronically
altered post-TBI gene expression in our experimental
model
Our previous study indicated regulated expression of ap-
proximately 5000 genes in the perilesional cortex and
Fig. 2 SignaLink transcription regulatory network (TRN) of Pax6 and its targets in the perilesional cortex. SignaLink network analysis revealed 300 targets, of
which 36 were upregulated and 59 were downregulated in the perilesional cortex 3 months post-TBI. Color codes: blue circle, downregulation after TBI; yel-
low circle, upregulation after TBI; white circle, no change in gene expression after TBI; green line, transcriptional interaction with Pax6; black line,
inter-target interaction
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1900 in the thalamus at 3 months after lateral FPI-
induced TBI. in particular, we found a positive enrich-
ment of inflammation-related genes and downregulation
of ion channel-related genes [69]. The mechanisms that
regulate chronic gene expression, however, remained un-
clear. Our transcriptomic data suggest that gene expres-
sion alterations could not be explained only by changes
in the local cell populations [69]. One potential major
regulator could be DNA-methylation, which regulates
gene expression in several brain diseases, including Alz-
heimer’s’ disease [19], Parkinson’s disease [51], amyo-
trophic lateral sclerosis [32], epilepsy [127], and TBI [39,
83, 102, 106]. To explore the significance of DNA methy-
lation as a regulator of chronically detected transcripto-
mics changes, we carried out genome-wide MBD-seq and
RNA-seq from the perilesional cortex, ipsilateral thalamus,
and ipsilateral hippocampus at 3 months post-TBI.
Regulated methylation was associated with altered
gene expression only in the perilesional cortex. GSEA
analysis revealed that the most enriched DNA methyla-
tion patterns in the perilesional cortex after TBI were in
the gene promoter area. Specifically, MBD-seq indicated
altered methylation in promoters of the Lrp1b, Gpr12,
Wrd26, and Ppid genes. Pyrosequencing, however, did
not confirm the sequencing data. This could relate to a
low, although consistent, read count per methylation site
in the promoter region (< 200) in the MBD-seq. Our
negative findings are in agreement with previous studies
in fluid-percussion injury, controlled cortical injury,
weight-drop, and blast-induced TBI models, which re-
ported no changes in the promoter methylation of
Lrp1b, Gpr12, Wrd26 and Ppid genes in cortical, hip-
pocampal, or amygdaloid tissue sampled 3 days to
8 months post-injury [39, 83, 102, 106]. We were not
able to reproduce the altered methylation in the rat cor-
tex at 8 months after blast TBI [39], in the rat amygdala
at 48 h to 30 d after weight-drop–induced TBI [102], in
the rat hippocampus at 3 and 14 d after controlled cor-
tical impact [106], in the rat hippocampus at 7 d after
fluid-percussion injury [83], or in the rat hippocampus
3 months after lateral fluid-percussion injury [20]. This
is likely related to the different injury types and post-
injury delays between the present and previous experi-
mental studies.
Fig. 3 SignaLink transcription regulatory network (TRN) of Tp73 and its targets in the perilesional cortex. SignaLink network analysis revealed 54 targets, of
which five were upregulated and 11 were downregulated in the perilesional cortex 3 months post-TBI. Color codes: blue circle, downregulation after TBI;
yellow circle, upregulation after TBI; white circle, no change in gene expression after TBI; green line, transcriptional interaction with Tp73; black line,
inter-target interaction
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TRN analysis revealed transcription factors Cebpd, Pax6,
Spi1 and Tp73 as regulators of chronically altered post-TBI
gene expression
To identify the master switch that regulates the mas-
sively altered gene expression at 3 months post-TBI, we
next investigated the possible contribution of transcrip-
tion factors by integrating transcriptomics data into the
Signalink 2.0 database. Laboratory validation of top hits
using ddPCR confirmed the predicted mRNA upregula-
tion of four transcription factors, Pax6, Tp73, Cebpd,
and Spi1, in the perilesional cortex.
Pax6 showed a 6.7-fold upregulation, and almost 30%
(91 or 300) of its target genes were regulated in the peri-
lesional cortex. The function of Pax6 in the cerebral
cortex is unknown. In the hippocampus, Pax6 controls
the differentiation and migration of neuronal progenitor
cells (NPC) [37], which show regenerative potential after
ischemic injury [88]. Moreover, overexpression of Pax6
improved the cellular viability of SH-SY5Y cells exposed
to neurotoxin [119]. These studies suggest that upregu-
lation of Pax6 after TBI could play a reparative role.
Tp73 showed a 1.6-fold upregulation, and approxi-
mately 30% (15 of 54) of its target genes were regulated in
the perilesional cortex after TBI. The Tp73 gene has two
promoters, producing two protein isoforms with different
functions [86]. The ΔNp73 isoform is anti-apoptotic dur-
ing development of the mouse superior cervical ganglion
neurons [95]. Furthermore, ΔNp73 is vital for long-term
Table 3 SignaLink 2.0 transcription regulatory network (TRN) analysis of differentially expressed transcription factors and their
up-regulated and down-regulated target genes in the perilesional cortex and the ipsilateral thalamus at 3 months after traumatic
brain injury. The same targets that were up-regulated both in the perilesional cortex and ipsilateral thalamus or down-regulated both
in the perilesional cortex and ipsilateral thalamus are bold fonts
Perilesional cortex Ipsilateral thalamus
TF Log2FC FDR Altered
targets/
all
targets
Upregulated
TF targets
Downregulated
TF targets
Log2FC FDR Altered
targets/
all
targets
Upregulated
TF targets
Downregulated
TF targets
Cebpd 1.835 3.78E-034 1/1 IGF1 – 1.261 7.47E-005 1/1 IGF1 –
Etv4 −1.105 2.03E-008 0/1 – – −0.697 0.00523964 0/1 – –
Myb 1.350 0.0042262 0/3 – – ns ns – – –
Pax6 1.186 5.97E-022 91/300 ABCA1, ABL1,
BMP6, BTK, CAV2,
CDKL1, DAB2,
DAPP1, ERBB2IP,
FGFR1, FGR,
FOXO1, FYB, GAB1,
IL21R, ITGA8,
ITGB1, MAP3K1,
MET, MICAL1,
MTSS1, NEDD1,
NIM1, PRKD1,
PTPRZ1, ROR2,
SKAP2, STK10, SYK,
TGFA, TICAM2,
UBE2U
AKT3, ARHGAP32,
ATF2, BIRC6, BMPR2,
CAMK1D, CHN1,
CHRNA7, CNKSR2,
CTNND2,DAB,
DMXL2, EFNA5,
EPHA7, EPHB2,
ERBB4, ESRRG,
GABRB3,
GRB2,GRIA1, GRIA4,
GRIK3, GRIN2A,
ITPR1, MAGI2,
MAP3K13, MAPK10,
MAPK8IP3, MEF2C,
MRAS, NEDD4L,
NLK, NRD1, NRG1,
NRG3, NUAK1, PAK7,
PAM, PCSK5, PDE4D,
PLCB1, PRKCA,
PRKCB, PTPRG,
PTPRJ, PTPRK, PTPRT,
RAB14, RAP1GDS1,
RGS7, ROCK2,
RPS6KC1, RPTOR,
SH3GL2, SNRK,
SORBS2, TRIM33,
TTBK2, ZFYVE9
0.779 8.41E-5 33/300 ABCA1, ATF1,
BTK, DAPP1,
EPHB1,
ERBB2IP,
ERBB4, FGF2,
FGR, GAB1,
GRB14, IL21R,
INPP5D,
ITGAM
ITGB1, PKP4,
PRKCA, TCF4,
TGFA
ARHGAP32,
CAMK1D,
CHN1, DAPK1,
GRM1, MAP3K14,
MAPK10,
NEDD4L, NRG2,
PRKCB,
RAP1GDS1, SRC,
STRADB, TRIO
Spi1 1.021 2.88E-011 1/3 LSP1 – 1.310 8.57E-006 1/3 LSP1 –
Tp73 1.328 0.01004339 15/54 TGFA, PTPN22,
CDK1, PDGFC,
NOTCH1
BDNF, RGS7, ERBB4,
SNCA, PRKCE, PTPRJ,
NEDD4L, KPNA1,
APBB2, STAM,
MYO3B
ns ns 6/55 MYLK,
NEDD4L
RRAD, TGFA,
ERBB4, PCNA
Abbreviations: FDR false discovery rate, ns non-significant, TF transcription factor
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survival of mouse superior cervical ganglion and cortical
neurons [66, 94]. The TAp73 isoform, however, induces
apoptosis in SAOS-2 and medulloblastoma cell cultures
[11, 50]. Further studies are needed to explore the func-
tional consequences of Tp73 upregulation after TBI.
Cebpd, also known as NF-IL6β, regulates immune and
inflammatory responses [57, 101]. Cebpd showed a 2.6-
fold upregulation, and its predicted target gene, IGF-1,
was also upregulated in the perilesional cortex at 3 months
post-TBI. There are some reports of increased expression
of Cebpd in the cortex already at 2 h to 7 d after injury in
various experimental models of TBI, including a con-
trolled cortical impact mouse model [48, 105, 128] and a
weight-drop rat model [16, 123]. These studies propose a
wide time window for the post-injury regulation of Cebpd
and its target IGF-1. It remains a testable hypothesis that
chronic upregulation of Cebpd and IGF-1 genes relates to
the control of chronic inflammation after TBI, as recently
suggested in favorable proof-of-concept preclinical studies
in injury models [75, 96, 110, 120].
Spi1 showed a 1.8-fold upregulation at 3 months post-TBI.
Spi1 is expressed in microglia [126], which become activated
after TBI [13, 61, 124]. Spi1 encodes PU.1, which appears
vital for microglial survival [111]. Our TRN network analysis
revealed three gene targets for Spi1, and of those, Lsp1 was
upregulated in the perilesional cortex and ipsilateral thal-
amus at 3 months post-TBI. Lsp1 was reported to be upreg-
ulated in the rat cerebral cortex at 24 h after controlled
cortical impact-induced TBI [128]. Spi1 regulates monocyte
and macrophage differentiation [100], and has a crucial role
in the normal development of T cells, B cells, neutrophils,
and macrophages [82], which are important players in the
post-TBI systemic inflammatory response [110].
In summary, our findings indicate that four transcrip-
tion factors, Pax6, Tp73, Cepbd, and Spi1, serve as major
chronic post-TBI transcriptomics regulators, and are thus
potential targets for treatments.
Table 4 Gene expression validation of genes encoding
transcription factors using ddPCR in the rat perilesional cortex,
thalamus and hippocampus at three months after TBI
Cebpd Pax6 Spi1 Tp73
Perilesional cortex
Fold change 2.58 1.64 1.75 6.67
p-value 0.0003996 0.004795 0.007592 0.0007992
Thalamus
Fold change 1.55 1.13 1.65 0.55
p-value 0.2721 0.4559 0.06633 0.3884
Hippocampus
Fold change 0.74 0.91 1.00 0.79
p-value 0.1375 0.7308 0.6282 0.6282
Statistical significances: Fold change and corresponding p-value (< 0.05) are
shown in bolded font
Table 5 LINCS database analysis identified compounds that up-regulate or down-regulate the gene expression of Cebpd, Pax6, Spi1
and Tp73 transcription factors. Identification of compounds regulating the expression of transcription factors were carried out by
retrieving compound-induced transcription profiles in terminally differentiated neurons, terminally differentiated neurons treated
with KCl, and iPS-derived neural progenitor cells
TF Upregulating compounds Downregulating compounds
Cebpd aminobenztropine (NEU), BG-1002 (NEU.KCL), BG-1011 (NPC), BIIB021 (NPC), BRD-A06779035
(NPC), BRD-A70591769 (NEU), BRD-A75769921 (NEU.KCL), BRD-A92334183 (NEU), BRD-K01608965
(NPC), BRD-K07381195 (NPC), BRD-K12683703 (NPC), BRD-K15050703 (NPC), BRD-K15935695
(NPC), BRD-K16934333 (NPC), BRD-K20126873 (NPC), BRD-K21374126 (NPC), BRD-K23986500
(NPC), BRD-K24798550 (NPC), BRD-K25164076 (NPC), BRD-K25990552 (NEU), BRD-K28934562
(NPC), BRD-K30229575 (NPC), BRD-K32885145 (NPC), BRD-K36269259 (NEU), BRD-K36313546
(NPC), BRD-K36591038 (NPC), BRD-K36796217 (NPC), BRD-K39597586 (NPC), BRD-K40300908
(NPC), BRD-K41871066 (NPC), BRD-K43631199 (NPC), BRD-K44540157 (NPC), BRD-K49111930
(NPC), BRD-K54331210 (NPC), BRD-K55536701 (NPC), BRD-K57166447 (NPC), BRD-K58808184
(NPC), BRD-K59253994 (NPC), BRD-K62970326 (NPC), BRD-K63494246 (NEU), BRD-K64523453
(NPC), BRD-K65148580 (NPC), BRD-K65657366 (NPC), BRD-K72354054 (NPC), BRD-K73008154
(NPC), BRD-K77888550 (NPC), BRD-K78133682 (NPC), BRD-K79947405 (NPC), BRD-K80062189
(NPC), BRD-K80138901 (NPC), BRD-K80400482 (NEU), BRD-K85133207 (NPC), BRD-K86110682
(NPC), BRD-K91844626 (NEU), BRD-K93158953 (NPC), BRD-K99718824 (NPC), cabergoline (NEU),
chlorpromazine (NEU), deoxycholic-acid (NEU), econazole (NPC), farnesylthioacetic-acid (NPC),
fluspirilene (NEU), geldanamycin (NPC), GSK-461364 (NPC), GW-3965 (NPC), GW-441756 (NPC),
IQ1 (NEU), IQ1 (NPC), isoflupredone (NPC), ITSA-1 (NPC), IWP-2 (NEU), LY-255283 (NPC), LY-
294002 (NPC), menadione (NPC), NVP-BEZ235 (NPC), PD-173074 (NPC), PI-828 (NPC), quercetin
(NPC), R-96544 (NPC), scoulerine (NPC), serotonin (NPC), spermidine (NEU), SR-142948 (NEU), ST-
023431 (NPC), ST-056792 (NPC), suberoyl-bis-hydroxamic-acid (NEU), tamoxifen (NPC), tozasertib
(NPC), tranylcypromine (NEU.KCL), triacetylresveratrol (NPC), trichostatin-a (NEU), trifluridine
(NPC), vorinostat (NPC)
BRD-K89824424 (NPC), O-1918 (NPC)
Pax6 acetyl-farnesyl-cysteine (NEU.KCL), BRD-K02409808 (NEU), BRD-K24656059 (NPC), BRD-K45842176
(NPC), clofibric-acid (NPC), rolipram (NPC), SKF-96365 (NPC), thioproperazine (NPC)
apicidin (NEU.KCL), BG-1016 (NPC), BRD-K37650321 (NEU),
chrysamine-g (NEU), proadifen (NPC), XMD-1150 (NEU)
Spi1 BRD-K39172790 (NEU), timosaponin (NEU) AS-703026 (NPC), genistein (NPC), U-0126 (NPC)
Tp73 BRD-K16827616 (NPC), BRD-K78133682 (NPC), RG-14620 (NPC), trimipramine (NEU), wortmannin
(NEU)
–
Abbreviations: NEU terminally differentiated neurons, NEU.KCL terminally differentiated neurons treated with, NPC iPS-derived neural progenitor cells,
TF transcription factor
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LINCS analysis revealed transcription factor-targeting
antidepressants and anti-cancer drugs as novel treatment
candidates for TBI
Next, we performed a LINCS analysis to identify com-
pounds that modulate the gene expression of Pax6,
Tp73, Cepbd, or Spi1. The largest number of com-
pounds identified targeted Cebpd. Most of the com-
pounds upregulating Cebpd were bioactive (starting
with BRD) without any known therapeutic actions. The
analysis, however, also identified antidepressants and
anti-cancer drugs that are already used in the clinic.
Tranylcypromine, an antidepressant and monoamine
oxidase inhibitor (MAO-I) [29], is a promising therapy
as MAO-Is have neuroprotective effects in mice with
TBI [44]. Tranylcypromine also alleviates neurodegener-
ation and inflammation by inhibiting prostacyclin and
arachidonic acid release in calf primary endothelial cells
[34, 43]. LINCS analysis also revealed fluspirilene and
chlorpromazine as upregulators of Cepbd. Duotherapy
with chlorpromazine and promethazine was demon-
strated to be neuroprotective when assessed at 24 h after
brain ischemia in rats [35]. Chlorpromazine suppressed
neuronal apoptosis in the rat parietal cortex and the
CA1 subfield of the hippocampus when assessed at 24 h
after ethanol-induced apoptosis [131]. Chlorpromazine
also reduced the cerebral infarct size when assessed at
24 h post-ischemia in rats [68].
In addition to compounds used in psychiatry, LINCS
analysis revealed an anti-cancer drug, vorinostat, a his-
tone deacetylase inhibitor (HDAC1–3 and 6) [77] as an
upregulator of Cepbd. Vorinostat attenuated neurode-
generation and improved neurological outcome when
assessed at 24 h after stroke in rats [117]. Interestingly,
valproate, another HDAC inhibitor (HDAC1–3 and 8)
[6], is neuroprotective and anti-inflammatory in rodent
models of TBI and ischemia [18, 55, 132]. Tamoxifen
was another upregulator of Cepbd identified by the
LINCS analysis. Tamoxifen is a selective estrogen receptor
modulator [107] used to treat breast cancer [33]. Tamoxifen
reduced the cerebral infarct volume and neuronal apoptosis
when assessed at 72 h after fluid-percussion injury in rats
[121]. LINCS analysis also revealed two compounds that
downregulated Cebpd, O-1918 and BRD-K89824424. In-
formation available from O-1918 indicates that it is a can-
nabidiol analog, acting as a selective antagonist of abnormal
cannabidiol at the non-CB1/CB2 endothelial receptor [89,
135]. Interestingly, another cannabinoid receptor antagon-
ist, AM630, counteracted the recovery-enhancing effects of
leptin [71]. Moreover, SR144528, a cannabinoid receptor
antagonist increased TNFα gene expression 24 h after
mouse controlled cortical impact (CCI), suggesting that it
enhances the inflammatory response [2]. Taken together,
these studies suggest that upregulation of Cebpd favorably
modifies the post-TBI outcome.
LINCS analysis revealed SKF-96365, thiopropera-
zine, and rolipram as upregulators of Pax6. SKF-96365
is an inhibitor of receptor-mediated calcium entry [84].
In an in vitro model of bovine brain microvessel endo-
thelial cells, SKF-96365 decreased blood-brain barrier
permeability [1], a major pathology in TBI. Thioproper-
azin is a neuroleptic that increases dopamine release
[12]. Interestingly, dopamine release was decreased at
1 week after TBI in the rat CCI model [109], and an in-
crease in dopamine level by methylphenidate improved
spatial memory based on a shorter Morris water-maze
latency at 14 d after rat CCI [58]. Rolipram, an anti-
depressant, MAO-I, and phosphodiesterase (PDE) IV in-
hibitor, also upregulates Pax6 gene expression. It
suppresses cytokine production in human and rat T cells
[114]. Moreover, rolipram inhibits neuronal damage in
gerbil CA1 hippocampus 7 d after stroke [53]. Rolipram
also reduced infarct size, improved neurological out-
come, increased anti-inflammatory cytokines, and de-
creased pro-inflammatory cytokines at 24 h after mouse
focal cerebral ischemia [62]. LINCS analysis revealed
that Pax6 was downregulated by proadifen, a cyto-
chrome P-450 inhibitor [10], and by apicidin, a histone
deacetylase inhibitor [41]. Interestingly, apicidin induced
apoptosis in MCF-7 cells through cell cycle regulatory
proteins [45] and reversed nitric oxide and inducible nitric
oxide synthase expression induced by dexamethasone and
RU24858 in a mouse macrophage cell culture [40]. Taken
together, upregulation of Pax6 gene expression appears to
be a target for favorable modulation of the post-TBI out-
come by reversing the reduced dopamine release and re-
ducing neuroinflammation via cytokine release, as
suggested by studies of thioproperazine and rolipram.
Moreover, both Cepbd and Pax6 are upregulated by com-
pounds with an MAO-I mechanism, and are predicted to
have favorable effects.
LINCS analysis revealed two compounds that upregu-
late Spi1. From these, timosaponin AIII is a candidate
anti-cancer drug [52, 118]. It reverses scopolamine-
induced memory impairment in mice [67]. LINCS ana-
lysis revealed three compounds that downregulated
Spi1. AS-703026 (also known as pimasertib) and
U0126 are MEK1/2 inhibitors [30, 56]. U0126 has favor-
able effects on recovery in various in vivo brain injury
models. For example, it reduced infarct size when
assessed at 24 h after middle cerebral artery occlusion in
rats [27], lesion size when analyzed at 7 d after in mice
injured with controlled cortical impact [87], and micro-
glial activation in the ischemia model of spinal cord in-
jury in rats [73]. Genistein, a phytoestrogen with a
broad spectrum of pharmacological properties, inhibits
protein tyrosine kinases and topoisomerase II, and ex-
hibits estrogen-like activity [23, 93]. Genistein showed
neuroprotective effects when assessed at 48 h after
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weight-drop–induced TBI [113] and at 24 h after focal
cerebral ischemia in rats [4]. Whether downregulators of
Spi1 will have favorable effects on more chronic post-
TBI outcome remains to be investigated.
LINCS analysis revealed three compounds with some
prior information of biological effects, all of which upregu-
lated Tp73. Wortmannin, a radiosensitizer, is a phosphoi-
nositide 3-kinase inhibitor [5] that also inhibits mTOR in
vitro, a pathway involved in post-TBI recovery and epilepto-
genesis in several post-injury animal models [8, 92]. Trimi-
pramine is a tricyclic antidepressant [103] that reduced
interferon-γ production, suppressed T-cell proliferation, and
increased interleukin-12 production in concanavalin A-
stimulated human whole blood cultures [21]. The effects of
trimipramine on brain injury, however, are poorly de-
scribed. RG-14620 is a protein tyrosine kinase inhibitor with
antiproliferative effects [134]. Compounds that upregulate
Tp73 expression are interesting candidates for further
studies. For example, trimipramine is already used in
the clinic and could be repurposed to improve outcome
after TBI.
Conclusions
This is the first analysis of chronic regulation of gene ex-
pression after TBI, demonstrating that chronic post-TBI
transcriptional regulation is more under the control of tran-
scription factors than DNA methylation. In particular, four
upregulated transcription factors Pax6, Tp73, Cebpd, and
Spi1, appeared as potent regulators of chronic post-TBI
gene expression. They regulate the molecular networks
contributing to post-injury secondary damage, including
apoptosis and inflammation, strengthening the feasibility of
therapeutically targeting these molecular networks even
after the acute post-TBI period. To complement
hypothesis-driven therapeutic approaches, our systems-
biology driven unbiased LINCS database analysis revealed
several novel treatment candidates. In particular, our data
together with a literature search of effects in in vitro and in
vivo models of brain injury revealed that antidepressant/
neuroleptics such as trimipramine, rolipram, fluspirilene,
and chlorpromazine, as well as the anti-cancer therapies
pimasertib, tamoxifen, and vorinostat are candidates for
further testing to favorably modulate regulated transcripto-
mics networks and post-TBI outcome.
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